JP2024514293A5 - - Google Patents

Info

Publication number
JP2024514293A5
JP2024514293A5 JP2023560269A JP2023560269A JP2024514293A5 JP 2024514293 A5 JP2024514293 A5 JP 2024514293A5 JP 2023560269 A JP2023560269 A JP 2023560269A JP 2023560269 A JP2023560269 A JP 2023560269A JP 2024514293 A5 JP2024514293 A5 JP 2024514293A5
Authority
JP
Japan
Prior art keywords
contrast agent
radioligand
less
concentration
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514293A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/058754 external-priority patent/WO2022207906A1/en
Publication of JP2024514293A publication Critical patent/JP2024514293A/ja
Publication of JP2024514293A5 publication Critical patent/JP2024514293A5/ja
Pending legal-status Critical Current

Links

JP2023560269A 2021-04-02 2022-04-01 前立腺がんの診断方法 Pending JP2024514293A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305432 2021-04-02
EP21305432.3 2021-04-02
PCT/EP2022/058754 WO2022207906A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer

Publications (2)

Publication Number Publication Date
JP2024514293A JP2024514293A (ja) 2024-04-01
JP2024514293A5 true JP2024514293A5 (cg-RX-API-DMAC7.html) 2025-04-10

Family

ID=75588163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560269A Pending JP2024514293A (ja) 2021-04-02 2022-04-01 前立腺がんの診断方法

Country Status (9)

Country Link
US (1) US20240181092A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313175A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514293A (cg-RX-API-DMAC7.html)
KR (1) KR20230165761A (cg-RX-API-DMAC7.html)
CN (1) CN117120100A (cg-RX-API-DMAC7.html)
CA (1) CA3215723A1 (cg-RX-API-DMAC7.html)
IL (1) IL307381A (cg-RX-API-DMAC7.html)
TW (1) TW202304531A (cg-RX-API-DMAC7.html)
WO (1) WO2022207906A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN120897762A (zh) * 2023-04-12 2025-11-04 康奈尔大学 用于治疗癌症的放射治疗缀合物
WO2026027442A1 (en) 2024-08-01 2026-02-05 Novartis Ag Synthesis of a precursor of radiopharmaceutical products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
SMT202300035T1 (it) * 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
KR20240027896A (ko) * 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법

Similar Documents

Publication Publication Date Title
EP3498308B1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
EP3766521B1 (en) Pharmaceutical composition containing 211at-labeled amino acid derivative, and method for producing said pharmaceutical composition
US11730834B2 (en) Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
CN111565762A (zh) 使用靶向放射治疗(trt)来驱动对免疫疗法的抗肿瘤免疫反应
KR20220063214A (ko) Grpr 길항제의 방사성표지 방법 및 이의 키트
US12296030B2 (en) Conjugates and their use as imaging agents
US20240181092A1 (en) Diagnostic methods of prostate cancer
US20230398240A1 (en) Therapeutic radiolabelled conjugates and their use in therapy
JPH04505622A (ja) ヒトに有効な↑9↑9↑mTc(III)心筋造影剤
JP2026505341A (ja) 神経膠芽腫を治療するための方法
US20250269072A1 (en) Processes for preparing radiolabelled conjugates
US20230330276A1 (en) Formulations and kits for radiotherapy and diagnostic imaging
US20260077072A1 (en) Methods and compositions for imaging malignancies in the bone marrow
US20250387523A1 (en) Combination therapy of radionuclide complex
US20230064292A1 (en) Methods of treating psma-positive cancer using radionuclide therapy
KR20260014588A (ko) 전립선암의 진단 및/또는 치료 방법
WO2025145255A1 (en) Lat-1 targeting amino acid derivatives and uses thereof
CN119101130A (zh) 一种用于诊断和治疗高表达cxcr4癌症的靶向剂
HK40008701B (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide